General Profile Company Name: Apogenix GmbH CEO: Dr. Thomas Hoeger Address: Im Neuenheimer Feld 584, 69120 Heidelberg, Germany Website: www.apogenix.com Origin: Spin out from DKFZ Nb of employees: 28 Annual turn over: Contact (Name, E-Mail): contact@apogenix.com			Summary: Apogenix is a biopharmaceutical company developing novel drugs for the treatment of malignant and inflammatory diseases. Apogenix' compounds exert their therapeutic effect by targeted modulation of signal pathways which play an important role in a variety of malignant and inflammatory diseases.  The company currently concentrates on two projects (APG101 and IL-4 blocker). After the successful phase I study on APG101 in May 2009, Apogenix is currently preparing further clinical studies in patients.				
Value chain Research		Busines				<b>Field</b> ⊠Cancer	
☐ Research ☐ Preclinical develop ☐ Clinical developme ☐ Manufacturing ☐ Marketing / distribution	ent	nt ⊠Bio □Coi □Sci n □Noi		harmaceuticals copharmaceuticals contract Organisation cientific service on-scientific service upplier		☐Infection☐CNS☐Metabol☐Orphan☐Auto-im	us Diseases lism Disorders Diseases Imune Diseases I Devices
☐ Gene / genomics ☐ Protein / proteomics ☐ Chemistry ☐ Vaccines ☐ Tissue / cells ☐ Medical devices ☐ Lab equipment	in vitro model		Know-how, expertise Construction of innovative biopharmaceutical Preclinical and clinical development  ystem ent				
Product Pipeline Preclinical	Phase I		Phas	e II	Pha	se III	MA
Alzheimer's disease							
Cancer		AF	PG101				
MS Other							
Needs and interes  R&D partnership Commercial allia Commercial deve	nce – co-marke	ting A					s that have an interest sive worldwide license

General Profile Company Name: Biorep CEO: Martin F. Trinkner Address: 74889 Sinshei Website: www.biorepair Origin: Nb of employees:6 Annual turn over: ca. 1 I Contact (Name, E-Mail)	m Blumenstr. 4 .com Mio.	BioRegio Rhei with Universitie produce diagno parasitological The fast growin diagnostic test BioRépair.	Summary: BioRépair® founded 1997 in the innovative BioRegio Rhein Neckar close to Heidelberg.In cooperation with Universities and private institutes we develope and produce diagnostics for immunological, microbiological and parasitological detections.  The fast growing market of Point of care tests and rapid diagnostic test kits is anew and important marketing fieldof BioRépair.				
Value chain  ☐ Research ☐ Preclinical develop ☐ Clinical developme x☐ Manufacturing x☐ Marketing / distrib	ment	ess Model Pharmaceuticals Biopharmaceutical Contract Organisa Scientific service Non-scientific serv Supplier	s x In cition CN	Field  x Cancer  x Infectious Diseases  CNS  Metabolism Disorders  Orphan Diseases  Auto-immune Diseases  Medical Devices  Other			
Technology, produ		Sales in Ger	how, expertise and Marketing of ra many and Austria.	apid diagnostic test systems			
Product Pipeline Preclinical Alzheimer's disease Cancer	Phase I	Phase II	Phase III	MA			
MS Other							
Needs and interes  □R&D partnership x□Commercial allia □Commercial deve	ance – co-marketing	Details Distribution partrest systems.	nership for rapid tes	st kits and microbiological			

			Summary:					
CEO: Dr. Steffen Hüttne				Software development for Research, Production and Industry				
72072 Tübingen Website: www.h-net.com Origin: 1992 Nb of employees: 30 Annual turn over: 2,4 millions € Contact (Name, E-Mail): Dr. Steffen Hüttner; steffen.huettner@h-net.com			Technical-scientific service company with certificated process along DIN 9001:2000, specialized in consulting, process management and individual software development in Life Sciences (software development, automation, cross linking) and automotive/engineering solutions (automatic testing, sensors and measurements as well as factory data capture). IdeenScout process which improves your innovation management.					
Value chain	В	Business Mod		Field Cance				
☐Research ☐Preclinical develop ☐Clinical developm X Manufacturing ☐Marketing / distrib	ent	☐Biopharm ☐Contract (☐Scientific	narmaceuticals opharmaceuticals ontract Organisation cientific service on-scientific service pplier		r ous Diseases olism Disorders n Diseases mmune Diseases al Devices			
Tochnology prod	ucte and convico	ne .						
	□Vaccines       X Informatics         □Tissue / cells       □Drug Delivery S         □Medical devices       □Imagery         X Lab equipment       □Drug Diagnostic         □Drug Developm       □Drug Discovery			ient				
Preclinical	Phase I	Pha	se II	Phase III	MA			
Alzheimer's disease Cancer								
MS								
Other								
Needs and interes  R&D partnership X Commercial allian X Commercial deve	nce – co-marketin	<b>Details</b>						

Summary: Insilico Biotechnology predicts and optimizes

**General Profile** 

Company Name:Insilico Biotech CEO:Klaus Mauch Address: Nobelstr. 15 Website: www.insilico-biotechno Origin: Stuttgart Nb of employees: 10 Annual turn over: 0.5 Mio EUR Contact: klaus.mauch@insilico-biotechnology.com	industri renown Insilico produc proprie compu	biotechnological processes for the chemical and healthcare industries. Since 2005, Insilico provides internationally renowned expertise and systems biotechnology services. Insilico's competitive advantage is its proven track record of producing new insights and IP for customers using its proprietary software, databases and high performance computing facilities. Insilico is a privately-owned company, located in Stuttgart, Germany.					
Value chain  Research Preclinical development Clinical development Manufacturing Marketing / distribution		Business Model  ☐ Pharmaceuticals ☐ Biopharmaceuticals ☐ Contract Organisation ☐ Scientific service ☐ Non-scientific service ☐ Supplier			CNS Metabo Orphar Auto-in	us Diseases Dism Disorders Diseases Diseases Diseases I Devices	
☐ Protein / proteomics ☐ Chemistry ☐ Vaccines ☐ Tissue / cells ☐ Medical devices ☐ Lab equipment ☐	Screening		Know-how, expertise By building better and innovative integrated mod of complex cellular processes, Insilico sets new standards in systems biotechnology as a leading solution provider to the Life Sciences industries.			, Insilico sets new nology as a leading	S
Alzheimer's disease Cancer MS Other	hase I	Phas	se II	Phas	e III	MA	
Needs and interest  ☐ R&D partnership ☐ Commercial alliance – co ☐ Commercial developmen ☐ Others		Details					

General Profile Company Name: Logopharn CEO: Dr. Uwe Sc. Address: Schlossstr 79232 Mar Website: www.logop Origin: 2005 (priv No of employees: 4 Annual turn over: Contact (Name, E-Mail): u.schulte@	LOGOF biomarl in Freib experts term ex innovat membra develop identific micropri free qua advance	Summary LOGOPHARM GmbH is engaged in proteomic target and biomarker R&D. The biotech company was established 2005 in Freiburg (Germany) by a team of scientists and business experts. It combines proprietary proteomic technologies, long-term experience in functional membrane protein analysis and innovative drug development concepts with focus on membrane proteins and protein complexes. Proprietary developments include the CompleXio technology for identification of protein-protein interactions in native tissue, microproteomic analysis with ultimate sensitivity and label-free quantitative mass spectrometry. Based on this, we offer advanced proteomic R&D services, tools and antibodies as well as technology and target-related developments.					
Value chain  X Research  □ Preclinical development □ Clinical development □ Manufacturing □ Marketing / distribution	Biopharma Contract O Scientific se	harmaceuticals iopharmaceuticals contract Organisation cientific service lon-scientific service			Field  Cancer Infectious Diseases  X CNS Metabolism Disorders Orphan Diseases Auto-immune Diseases Medical Devices  X Other		
Technology, products  Gene / genomics  X Protein / proteomics  Chemistry  Vaccines (x) Tissue / cells  Medical devices  Lab equipment	and services Screening in vitro model in vivo model (x) Informatics Drug Delivery Imagery Diagnostic Drug Develop Drug Discove	y System	Know-how, expertise membrane proteins, protein biochemistry antibodies molecular physiology of ion channels and receptor mass spectrometry bioinformatics				
Product Pipeline Preclinical Alzheimer's disease Cancer MS Other	Phase I	Phas	e II	Phas	se III	MA	
Needs and interest  X R&D partnership  Commercial alliance – co-marketing  Commercial development  X Others		areas: - t	We look for customers and R&D partners in the following areas:  - target discovery and characterization - cell line development - antibodies and antibody validation				

General Profile Company Name: PAION CEO: Dr. Wolfgang Söh Address: Martinstr. 10-1 Website: www.paion.com Origin: Germany Nb of employees: 30 Annual turn over: 3,166 Contact (Name, E-Mail):	NAG ngen 2 Ger n The dru (2008) (2008) Hei PAI exp acq reg PAI	PAION is a biopharmaceutical company headquartered in Aachen, Germany. Since the acquisition of CeNeS Pharmaceuticals, which was completed in June 2008, the company has a second site in Cambridge, UK. The company is specializing in developing and commercializing innovative drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need. PAION intends further expand its portfolio of drugs by exploiting its core expertise in identifying high-potential compounds, licensing or otherwise acquiring them and advancing them through the clinical development and regulatory approval process.  PAION is listed at the Frankfurt Stock Exchange (Prime Standard Regulated Market, Stock Symbol PA8, ISIN DE000A0B65S3).						
Director Investor relati Public Relations r.penner@paion.com	ons &							
<ul> <li>☑Research</li> <li>☑Preclinical development</li> <li>☑Clinical development</li> <li>☑Manufacturing</li> <li>☑Marketing / distribution</li> </ul>		⊠Pha ⊠Bio □Co ⊠Sci □No □Sul	iness Model Pharmaceuticals Biopharmaceuticals Contract Organisation Scientific service Non-scientific service Supplier			Field  Cancer Infectious Diseases  CNS Metabolism Disorders Orphan Diseases Auto-immune Diseases Medical Devices Other		
Technology, produ	☐Scree ☐in vitro ☐in vivo ☐Inform ☐Drug I ☐Image ☐Diagn ☐Drug I	ning o model o model natics Delivery Sy		Know-ho	ow, exper	tise		
Product Pipeline Preclinical Alzheimer's disease	Phase	I	Phas	e II	Pha	se III	MA	
Cancer MS Other		4			2			
Needs and interes  R&D partnership Commercial allian Commercial deve	nce – co-mark		Details					

General Profile Company Name: Rentschler Biotechnologie GmbH CEO: Dr. Nikolaus F. Rentschler Address: Erwin-Rentschler-Strasse 21 Website: www.rentschler.de Origin: 1974 Nb of employees:450 Annual turn over: Contact (Name, E-Mail): Dr. Manfred Papaspyrou,			Summary: Rentschler Biotechnologie GmbH, Laupheim (Germany), is an international contract manufacturer with more than 30 years of experience in the development, production and approval of biopharmaceuticals in compliance with international GMP standards (EMEA / FDA). At present Rentschler Biotechnologie has nine stand-alone GMP suites with volumes of 30, 50, 250, 500 and 2,500 liters, allowing the production of material for clinical trials (phase I to III) and for market supply. In addition, Rentschler provides regulatory advice and fill and finish services.			
manfred.papaspyrou@rer	ntschler.de					
Value chain       Busines         □ Research       □ Ph         □ Preclinical development       X Bio         □ Clinical development       X Co         X Manufacturing       □ Sc         □ Marketing / distribution       □ No		X Biopharma X Contract O	narmaceuticals opharmaceuticals ntract Organisation cientific service on-scientific service		Field  Cancer Infectious Diseases CNS Metabolism Disorders Orphan Diseases Auto-immune Diseases Medical Devices  X Other Contract manufacturing of mammalian cell derived biopharmaceuticals for all therapeutic sectors	
Technology, produc	cts and service	es		<u> </u>		
X Gene / genomics x Protein / proteomics Chemistry Vaccines x Tissue / cells Medical devices Lab equipment	Screening in vitro magnitude in vivo magnitude in vivo magnitude in in vivo magnitude in	g nodel odel cs very System ic elopment	GMP-ce		rmaceutical Ingredients	
Product Pipeline : n Preclinical Alzheimer's	n/a Phase I	Pha	se II	Phase III	MA	
disease						
Cancer						
MS						
Other						

#### **Needs and interest**

Rentschler is seeking co-operations with pharma and biotech companies for contract manufacturing, production and registration of therapeutic proteins

General Profile Company Name: SymbioTec GmbH CEO: Prof. Michael Zeppezauer Address: Science Park 1, D-66123 Saarbrücken Website: www.symbiotec.biz Origin: private Nb of employees: 6 Annual turn over: Contact (Name, E-Mail): m.zeppezauer@symbiotec.biz			Summary: SymbioTec's goal is the development of oncolytic medicament based on the body's own proteins, histones, which are components of the innate immune system. These multifunctional proteins comprise hormonal, regulatory and protective functions, particularly cytotoxic activity against tumor cells and infectious microorganisms. Histones H1-based drugs have a broad therapeutic potential not only in hematopoietic cancers but also in solid tumors. First phase I/II clinical trial with 22 Acute Myeloid Leukemia patients proved the drug to be tolerated without side effects and showed first signs of therapeutic efficacy.						
X Clinical developme  ☐Manufacturing	□ Research       □ Ph         □ Preclinical development       X Bio         X Clinical development       □ Co         □ Manufacturing       □ So         □ Marketing / distribution       □ No			charmaceuticals contract Organisation cicientific service don-scientific service cupplier			Field X Cancer X Infectious Diseases  CNS Metabolism Disorders Orphan Diseases X Auto-immune Diseases Medical Devices Other		
☐Gene / genomics	□ Vaccines       □ Informatics         □ Tissue / cells       □ Drug Delivery         □ Medical devices       □ Imagery		nent	Clinical trial development					
Product Pipeline		-							
Preclinical Alzheimer's	Phase I		Phas	e II	Phase III		MA		
disease									
Cancer	X AML								
MS									
Other									
Needs and interest  R&D partnership X Commercial alliance – co-marketing X Commercial development Others		Details  SymbioTec is searching for partners for its further drug development such as pharmaceutical companies and investors. The company is interested in collaborations with pharmaceutical companies developing new drugs or diagnostics in areas such as cancer, antibiotics and autoimmune diseases.  SymbioTec also welcomes collaboration with other academic and industrial research groups with synergistic technologies and interest in protein drug development.							

General Profile Company Name: Therapy Co.KG CEO: Dr. Frank Kisch Address: Im Neuenheime 69120 Heidelbe Website: www.therapyse Nb of employees: 11 Annual turn over: 250.00	products in t nology + mar is 30 to 40 % been succes among other attaining in chemosensiti is on its way	<b>Summary:</b> TherapySelect focuses on the development and sale of products in the field of oncological diagnostics and aims to gain technology + market leadership in that segment. The companies target group is 30 to 40 % of the worldwide 50 million cancer patients. By now, TS has been successful in introducing the EDR®-assay to the German market, among others by persuading some of the major opinion leaders and by attaining insurance provider reimbursement for this tool of chemosensitivity diagnostics. The launch of its own BiochipSelect® assay is on its way. Results from ongoing development activities (in collaboration with major research institutions and funded by state agencies) will					
450.000 estim. Contact (Name, E-Mail): Dr. Frank Kischkel Phone: +49-6221-8936-2 Email: frank.kischkel@th	complete the 'spin-off' of the TS' competite commercialistic based on its	complete the product pipeline in the near future. Despite its origins as a 'spin-off' of the German Cancer Research Center (DKFZ) in Heidelberg, TS' competitive advantage lies in its renowned expertise in the commercialisation and marketing of cancer diagnostics. This experience -based on its rather unique customer service operations approach - can easily be made use of for related oncological products.					
Value chain  x Research  Preclinical development  x Clinical development  x Lab services  x Marketing / distribution		Biopharma Contract O x Scientific se Non-scienti Supplier	☐Pharmaceuticals☐Biopharmaceuticals☐Contract Organisatiox Scientific service☐Non-scientific service		Field x Cancer Infectious Diseases CNS Metabolism Disorders Orphan Diseases Auto-immune Diseases x Medical Devices		
Technology, product X Gene / genomics Protein / proteomics Chemistry Vaccines x Tissue / cells x Medical devices Lab equipment  Product Pipeline	☐Screening ☐in vitro mo ☐in vivo mo ☐Informatio	g odel odel os ivery System c relopment	when we shall be supported by the cancer within the German market. The key know-house some on work with fresh tumor samples. With regard to mercialisation expertise, the company excels in its effective client relationship management and in			ablishing, developing, ma ic products in the field of it. The key know-how con hereby laying an emphas es. With regard to its con mpany excels in its high nagement and in its pro	of n- sis n- lly
Preclinical	Phase I	Phas	e II	Phase III		MA	
Alzheimer's		1			· · · · · · · · · · · · · · · · · · ·		
disease Cancer		BiochipSe Genchip-		N/A		EDR-Assay <sup>®</sup>	
MS							
Other							
Needs and interest  A) Commercial alliance / Co-marketing  B) Lab partnership		markets in the near commerci lts gained starting p most cent large scal qualified a equipmen	Details: A.) TherapySelect's ambition to enter all relevant European markets in the field of oncology diagnostics and related products in the near future can only be pursued, if the company can unite the commercialisation processes of various products under its 'umbrella'. Its gained position within German oncologists offers an excellent starting point for North America based companies to 'conquer' this most central of all European markets, in order to then jointly pursue a large scale European expansion. B.) TherapySelect's staff is highly qualified and its laboratory facilities dispose of all 'state of the art' equipment. Therefore, it deems fit as an ideal lab hub for any new service in the field of oncology.				